Why insider trading matters?
Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2021-12-01 | Jones Erin | Chief Operating Officer | Sell | 1,000 | $13.01 | $13,010 | Yes |
| 2021-11-01 | Jones Erin | Chief Operating Officer | Sell | 1,000 | $11.14 | $11,140 | Yes |
| 2021-10-04 | Jones Erin | nan | Sell | 2,000 | $10.70 | $21,390 | Yes |
| 2021-09-08 | Jones Erin | nan | Sell | 2,000 | $11.37 | $22,748 | Yes |
| 2021-11-01 | Jones Erin | nan | Sell | 1,000 | $11.14 | $11,140 | Yes |
| 2021-10-04 | Jones Erin | nan | Sell | 2,000 | $10.70 | $21,390 | Yes |
| 2021-05-27 | Rousseau Raphael | nan | Sell | 2,900 | $9.00 | $26,112 | Yes |
| 2021-01-20 | Rousseau Raphael | nan | Sell | 30,000 | $20.04 | $601,269 | Yes |
| 2021-01-19 | Yelensky Roman | nan | Sell | 10,000 | $22.10 | $221,029 | No |
| 2020-12-30 | Woiwode Thomas | Director | Buy | 1,347,709 | $3.71 | $5,000,000 | No |
| 2019-08-21 | Rousseau Raphael | See Remarks | Sell | 10,000 | $10.76 | $107,631 | Yes |
| 2018-09-28 | Simon Nicholas | 10%-Owner, Director | Buy | 333,333 | $15.00 | $4,999,995 | Yes |
| 2018-09-28 | Clarus Lifesciences III, L.P. | 10%-Owner | Buy | 333,333 | $15.00 | $4,999,995 | Yes |
Insider Smart
Insider Smart